Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
NCT05607446 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · PHASE1 · terminated · last registry update 2024-11-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was closed per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.” | – | Registry record, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYSLTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-17Results posted on the registry: Susanna Naggie, MD, Ivermectin + Fluvoxamine (NCT04885530)
- 2025-11-14Results posted on the registry: Sanofi, Isatuximab IV + Isatuximab SC (NCT05405166)
- 2025-10-21Results posted on the registry: Sanofi, AGALSIDASE BETA (GZ419828) + Acetaminophen (NCT06019728)
- 2025-10-20Results posted on the registry: Janssen Research & Development, LLC, Dexamethasone + Montelukast (NCT05663866)
- 2025-09-17Also stopped (terminated): Sanofi, Isatuximab SAR650984 + Acetaminophen (paracetamol) or equivalent (NCT04294459)
- 2025-05-30Results posted on the registry: University of Colorado, Denver, Montelukast (NCT05362474)
- 2025-05-30Also stopped (terminated): University of Colorado, Denver, Montelukast (NCT05362474)
- 2025-01-22Results posted on the registry: National Cancer Institute (NCI), Ibrutinib + Steroid pulse (prednisone) (NCT04294641)
- 2024-12-24Phase 3 first posted: Phramongkutklao College of Medicine and Hospital, Montelukast + Montelukast Placebo (NCT06747130)
- 2024-11-18Also stopped (withdrawn): Vanderbilt University Medical Center, Montelukast Oral Granules (NCT03277170)
- 2024-08-16Results posted on the registry: Susanna Naggie, MD, Montelukast (NCT05894577)
- 2024-07-03Also stopped (terminated): Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Montelukast (NCT04695704)
- 2024-05-28Phase 3 first posted: University of KwaZulu, Budesonide/formoterol + standard of care (NCT06429475)
- 2024-04-02Phase 3 first posted: South Valley University, Montelukast 10 Mg Oral Tablet (NCT06340984)
- 2024-03-07Results posted on the registry: Emory University, Montelukast + Placebo oral tablet (NCT03991988)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision